ABBOTT LABORATORIES Operating Lease, Liability, Noncurrent
ABBOTT LABORATORIES (ABT) had Operating Lease, Liability, Noncurrent of $931.00 million as of 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-02-20
- 2025-12-31: Operating Lease, Liability, Noncurrent $931.00M.
- 2024-12-31: Operating Lease, Liability, Noncurrent $896.00M.
- 2023-12-31: Operating Lease, Liability, Noncurrent $949.00M.
- 2022-12-31: Operating Lease, Liability, Noncurrent $943.00M.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2025-12-31 | $931.00M 10-K · filed 2026-02-20 |
| 2024-12-31 | $896.00M 10-K · filed 2026-02-20 |
| 2023-12-31 | $949.00M 10-K · filed 2025-02-21 |
| 2022-12-31 | $943.00M 10-K · filed 2024-02-16 |
| 2021-12-31 | $956.00M 10-K · filed 2023-02-17 |
| 2020-12-31 | $902.00M 10-K · filed 2022-02-18 |
| 2019-12-31 | $755.00M 10-K · filed 2021-02-19 |
| 2019-09-30 | $702.00M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $670.00M 10-Q · filed 2019-07-31 |
| 2019-03-31 | $655.00M 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |